Emory University

Brown University

Duke University

The Rockfeller University

Stephen T Warren

Mark F Bear

Kimberly M Huber

Jack D Keene

Robert Darnell

Scott A Tenenbaum

Peng Jin

Stephanie Ceman

Jennifer C Darnell

Victoria Brown-Kennerly

mGluR5 antagonists are used for the treatment and prevention of disorders, including Fragile X, autism, mental retardation, schizophrenia and Down's Syndrome. The methods of the invention can be used to treat epilepsy and anxiety in a human having Fragile X syndrome, autism, mental retardation, schizophrenia and Down's Syndrome.

Methods of treating disorders with Group I mGluR antagonists

Compositions and methods for identifying and/or modulating RNA transcripts and/or genes involved in fragile X syndrome and other associated disorders are provided. In particular, RNA targets for fragile X mental retardation protein (FMRP) have been identified by a novel monoclonal antibody to FMRP and a consensus sequence for the RNA binding region has been identified. Arrays for identifying compounds, proteins, nucleotides, and the like that modulate the RNA targets or associated genes are provided. Additionally, methods for modulating RNA targets are provided.

Method and identification of downstream mRNA ligands to FMRP and their role in fragile X syndrome and associated disorders

Compositions and uses of mGluR5 antagonists for the treatment and prevention of neurological disorders, such as Fragile X, autism, mental retardation, schizophrenia and Down's Syndrome, are disclosed.

Methods of treating disorders with group I mGluR antagonists

Growing community of inventors

Atlanta, GA, United States of America

Stephen T Warren